Study M333
Study name | Milak MS 2016 |
Title | A pilot in vivo proton magnetic resonance spectroscopy study of amino acid neurotransmitter response to ketamine treatment of major depressive disorder |
Overall design | This pilot study sought to test the hypothesis that ketamine administration in depressed patients produces a rapid, robust surge in glutamatergic compounds in the medial prefrontal cortex (mPFC), as observed in rodent studies. The N-methyl-D-aspartate receptor antagonist ketamine can improve major depressive disorder (MDD) within hours. Ketamine (0.5 mg/kg intravenously) was administered to 11 depressed patients with MDD. To evaluate the putative role of glutamatergic and GABAergic systems in ketamine's antidepressant action, medial prefrontal cortical (mPFC) levels of glutamate + glutamine (Glx) and gamma-aminobutyric acid (GABA) were measured before, during, and after ketamine administration using proton magnetic resonance spectroscopy. Glx and GABA mPFC responses were measured as ratios relative to unsuppressed voxel tissue water successfully in 8/11 patients. |
Study Type | Type2; |
Data available | Unavailable |
Organism | Human; |
Categories of depression | Depressive disorder; Depression; Depression; |
Criteria for depression | DSM-IV diagnosed MDD, HAMD-17 >= 16 |
Sample size | 8 |
Tissue | Central; Brain; Medial prefrontal cortex; |
Platform | MRS; MRS: General Electric Signa EXCITE 3.0 T MR scanner (GE Healthcare, WI, USA); |
PMID | |
DOI | |
Citation | Milak MS, Proper CJ, Mulhern ST, et al. A pilot in vivo proton magnetic resonance spectroscopy study of amino acid neurotransmitter response to ketamine treatment of major depressive disorder. Mol Psychiatry 2016;21(3):320-7. |
Metabolite |
